Diabetes specialist Dexcom chooses Exyte to construct first facility in Asia

0
436

The US-based provider of diabetes care technology has planned a production area of ​​1.8 m² in Malaysia

Exyte, a specialist in high-tech plant design and construction, has received a fast-track project for Dexcom in Penang, Malaysia. This is the first manufacturing facility for the US-based diabetes care technology provider outside of the US.

Exyte supports Dexcom’s strategic growth plans as it expands manufacturing into Asia for the first time. The project is located in Batu Kawan, Penang, and has a gross floor area of ​​1.8 million square meters. It will house a continuous glucose monitoring system (CGM) manufacturing facility.

Important parts of the system are:

  • multi-storey clean rooms
  • a warehouse with a loading bridge
  • a three-story Central Utility Building (CUB)
  • A seven-story office building with a canteen and a recreation area as well as a seven-story multi-story park structure

The project will allow Dexcom to rapidly expand CGM production and increase the number of systems that can be shipped worldwide to meet growing demands.

“We selected Exyte to build our first manufacturing facility in Asia because of their ability to deliver rapid projects of this scale and complexity,” said David Arida, senior vice president of manufacturing operations at Dexcom.

Jack Lyons, Exyte’s Vice President, Biopharma and Life Sciences, Southeast Asia, said: “We are delighted to be selected as the prime contractor and trusted partner to deliver Dexcom’s first manufacturing facility in Asia, providing our customers with a fast time to market.” “